Vertex Pharmaceuticals, Inc. (VRTX) Tops Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $485.39 -2.24%
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q4 EPS of $0.86, $0.16 better than the analyst estimate of $0.70. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $518.36 million.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season
- Goldman Sachs reports global fund inflows for week of July 8
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
